CAJ | 학술논문

目的：探讨长期联用重组人血管内皮抑制素治疗晚期前列腺癌的临床疗效。方法分析28例晚期前列腺癌病例，实验组18例，对照组10例，对照组采用内分泌治疗及放射治疗，实验组在对照组的治疗基础上加用重组人血管内皮抑制素，检查血清总前列腺特异性抗原（TPSA）、游离前列腺特异性抗原（FPSA）水平，观察不良反应发生情况。结果实验组及对照组治疗后 FPSA、TPSA 均显著降低（P ＜0．01）。治疗3、6、12、28个月时实验组患者的 FPSA、TPSA 值均显著低于对照组（P＜0．01）。FPSA 及 TPSA 曲线图显示实验组各时间点的数值均低于对照组。实验组骨髓抑制Ⅱ度和Ⅲ度患者总例数显著高于对照组（P ＜0．01），2组患者凝血功能、胃肠道反应无显著差异（P ＞0．05）。肝功能检查见谷草转氨酶（AST）或谷丙转氨酶（ALT）水平轻度升高，经保肝治疗后好转，2组比较无显著差异（P ＞0．05）。结论联合重组人血管内皮抑制素治疗晚期前列腺癌优于单用内分泌及放射治疗，副作用以骨髓抑制为主。
목적：탐토장기련용중조인혈관내피억제소치료만기전렬선암적림상료효。방법분석28례만기전렬선암병례，실험조18례，대조조10례，대조조채용내분비치료급방사치료，실험조재대조조적치료기출상가용중조인혈관내피억제소，검사혈청총전렬선특이성항원（TPSA）、유리전렬선특이성항원（FPSA）수평，관찰불량반응발생정황。결과실험조급대조조치료후 FPSA、TPSA 균현저강저（P ＜0．01）。치료3、6、12、28개월시실험조환자적 FPSA、TPSA 치균현저저우대조조（P＜0．01）。FPSA 급 TPSA 곡선도현시실험조각시간점적수치균저우대조조。실험조골수억제Ⅱ도화Ⅲ도환자총례수현저고우대조조（P ＜0．01），2조환자응혈공능、위장도반응무현저차이（P ＞0．05）。간공능검사견곡초전안매（AST）혹곡병전안매（ALT）수평경도승고，경보간치료후호전，2조비교무현저차이（P ＞0．05）。결론연합중조인혈관내피억제소치료만기전렬선암우우단용내분비급방사치료，부작용이골수억제위주。
Objective To explore the clinical efficacy of long-term application of recombi-nant human endostatin on patients with advanced prostatic carcinoma.Methods Twenty-eight pa-tients with prostatic carcinoma were divided into control group (10 cases)treated with endocrine therapy and radiotherapy and experimental group (18 cases)added with recombinant human endo-statin.Serum total prostate specific antigen (TPSA)and free prostate specific antigen (FPSA)lev-els were detected and adverse responses were observed.Results FPSA and TPSA levels decreased evidently in both groups after treatment (P <0.01),and were obviously lower in experimental group than in control group 3,6,12 and 28 months after treatment (P <0.01).Additionally, their curve charts showed that their levels in each time point was lower in experimental group than in control group.The number of patients with myelosuppression in degrees Ⅱ and Ⅲ was markedly higher in experimental group than in control group (P <0.01),but there were no significant differ-ences in those with coagulation disorders and gastrointestinal responses (P >0.05).Liver function examination indicated that aspartate transaminase (AST)and alanine transaminase (ALT)had slight increase and were improved after liver-protection therapies,which had no significant differ-ences between two groups (P >0.05).Conclusion Combined application with recombinant human endostatin has better clinical efficacy than single utilization of endocrine therapy and radiotherapy on patients with advanced prostatic carcinoma,in which the myolesuppression is the primary adverse response.